The Q·Score Snapshot

LLY scores 7.9 out of 10, earning a "Bullish" label on Quantify's Q·Score system. The Q·Score aggregates fundamental strength, earnings momentum, analyst sentiment, and valuation signals into a single composite — a score in the upper tier of the range reflects broadly positive readings across most of those inputs, not any single outlier. The 7.9 here is driven by the combination of explosive growth metrics, high profitability, and strong analyst coverage consensus.

Business at a Glance

Eli Lilly is one of the world's largest pharmaceutical companies, operating within the Healthcare sector and best known for its diabetes and obesity drug portfolio — most notably its GLP-1 receptor agonist treatments, Mounjaro and Zepbound, which have become blockbuster products. The company also maintains significant franchises in oncology, immunology, and neuroscience. The current data profile is shaped almost entirely by the extraordinary commercial ramp of its weight-loss and diabetes medicines, which have driven revenue and earnings to levels that would have seemed implausible just a few years ago.

The Numbers That Stand Out

Revenue grew 55.5% year-over-year — an exceptional figure for a company already operating at mega-cap scale, with a market capitalisation of approximately $1.09 trillion. Earnings growth of 169.9% over the same period indicates that revenue is flowing through to the bottom line with significant operating leverage. The net profit margin sits at 35%, meaning Eli Lilly keeps $0.35 of every dollar of revenue as net income — a level more commonly associated with software businesses than pharmaceutical manufacturers. Return on equity (ROE) — a measure of how efficiently a company generates profit from shareholders' invested capital — stands at a striking 107.5%, which reflects both high profitability and the effect of the company's capital structure. Finally, LLY has beaten analyst EPS (earnings per share) estimates in 100% of reported quarters tracked in this dataset, a perfect beat rate that signals consistent outperformance against Wall Street's expectations.

What Analysts Think

Of the 28 analysts currently covering LLY, 77% carry a positive rating on the stock. The consensus price target sits at approximately $1,240, implying modest upside of roughly 1.9% from the current price of $1,216.95. That narrow gap between the current price and the consensus target suggests that, at present levels, analyst expectations are largely reflected in where the stock is already trading — though it is worth noting that consensus targets are revised regularly as new data emerges.

The Bigger Picture

Within the Healthcare sector, Eli Lilly stands as a clear outlier in terms of growth velocity — most large-cap pharmaceutical peers are posting revenue growth in the low-to-mid single digits, making LLY's 55.5% figure a genuine anomaly at this scale. The stock's forward P/E of 27.2 (the stock price divided by the next twelve months' expected earnings per share) is elevated relative to the broader market but notably more moderate than the triple-digit earnings growth rate might suggest, reflecting how rapidly the earnings denominator has expanded. Whether the GLP-1 wave sustains its momentum — through manufacturing capacity, competitive dynamics, and reimbursement trends — is the central question the data cannot yet answer, but the current fundamental snapshot is one of the most striking in the large-cap healthcare universe.